Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.10 per share for the year. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.29) per share.
ONCY has been the subject of several other research reports. Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th. Leede Financial downgraded shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research note on Wednesday, November 13th.
Check Out Our Latest Research Report on ONCY
Oncolytics Biotech Price Performance
Shares of ONCY traded up $0.05 during mid-day trading on Tuesday, hitting $0.79. The stock had a trading volume of 2,165,694 shares, compared to its average volume of 2,302,129. Oncolytics Biotech has a 52 week low of $0.67 and a 52 week high of $1.53. The business has a fifty day moving average price of $0.85 and a 200-day moving average price of $0.97. The firm has a market cap of $63.61 million, a P/E ratio of -2.94 and a beta of 1.24.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Oncolytics Biotech stock. International Assets Investment Management LLC raised its position in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) by 15.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 200,400 shares of the company's stock after acquiring an additional 26,069 shares during the quarter. International Assets Investment Management LLC owned approximately 0.26% of Oncolytics Biotech worth $186,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.82% of the company's stock.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
